Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Nitroprusside in Early Course Schizophrenia
NCT04986072Phase 2Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium nitroprusside in schizophrenia, schizoaffective disorder, sponsored by Beth Israel Deaconess Medical Center. Started Mar 2022; status: terminated.
02
Drugs
sodium nitroprusside
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT04986072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04986072.